{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:18:40Z","timestamp":1793992720728,"version":"4.8.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T00:00:00Z","timestamp":1655683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T00:00:00Z","timestamp":1655683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Mitsubishi Tanabe Pharma America, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s40268-022-00391-6","type":"journal-article","created":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T09:04:08Z","timestamp":1655715848000},"page":"205-211","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Analysis of the US Safety Data for Edaravone (Radicava\u00ae) From the Third Year After Launch"],"prefix":"10.1007","volume":"22","author":[{"given":"Angela","family":"Genge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin Rix","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Oskarsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kalin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3051-3953","authenticated-orcid":false,"given":"Stephen","family":"Apple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bower","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,20]]},"reference":[{"issue":"2","key":"391_CR1","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1056\/NEJMra1603471","volume":"377","author":"RH Brown","year":"2017","unstructured":"Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377(2):162\u201372.","journal-title":"N Engl J Med"},{"issue":"9 suppl","key":"391_CR2","first-page":"S175","volume":"24","author":"BR Brooks","year":"2018","unstructured":"Brooks BR, Jorgenson JA, Newhouse BJ, Shefner JM, Agnese W. Edaravone in the treatment of amyotrophic lateral sclerosis: efficacy and access to therapy\u2014a roundtable discussion. Am J Manag Care. 2018;24(9 suppl):S175\u201386.","journal-title":"Am J Manag Care"},{"issue":"5\u20136","key":"391_CR3","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1080\/21678421.2019.1612435","volume":"20","author":"J Raymond","year":"2019","unstructured":"Raymond J, Oskarsson B, Mehta P, Horton K. Clinical characteristics of a large cohort of US participants enrolled in the National Amyotrophic Lateral Sclerosis (ALS) Registry, 2010\u20132015. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(5\u20136):413\u201320.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"5\u20136","key":"391_CR4","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3109\/21678421.2014.903974","volume":"15","author":"S Paganoni","year":"2014","unstructured":"Paganoni S, Macklin EA, Lee A, Murphy A, Chang J, Zipf A, et al. Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis (ALS). Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(5\u20136):453\u20136.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"391_CR5","unstructured":"Radicava\u00ae (edaravone injection) [package insert]. Jersey City: Mitsubishi Tanabe Pharma Corporation; August 2018."},{"key":"391_CR6","unstructured":"Rilutek\u00ae (riluzole) [package insert]. Bridgewater: Sanofi-aventis U.S. LLC; November 2012."},{"issue":"7","key":"391_CR7","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S1474-4422(17)30115-1","volume":"16","author":"Writing Group; Edaravone (MCI-186) ALS 19 Study Group","year":"2017","unstructured":"Writing Group; Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16(7):505\u201312.","journal-title":"Lancet Neurol"},{"issue":"7\u20138","key":"391_CR8","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1080\/21678421.2019.1645858","volume":"20","author":"C Jackson","year":"2019","unstructured":"Jackson C, Heiman-Patterson T, Kittrell P, Baranovsky T, McAnanama G, Bower L, et al. Radicava (edaravone) for amyotrophic lateral sclerosis: US experience at 1 year after launch. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(7\u20138):605\u201310.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"2","key":"391_CR9","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jaci.2013.08.016","volume":"133","author":"RA Wood","year":"2014","unstructured":"Wood RA, Camargo CA Jr, Lieberman P, Sampson HA, Schwartz LB, Zitt M, et al. Anaphylaxis in America: the prevalence and characteristics of anaphylaxis in the United States. J Allergy Clin Immunol. 2014;133(2):461\u20137.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"391_CR10","first-page":"17","volume":"134","author":"DE Cole","year":"1986","unstructured":"Cole DE. Sulfites and parenteral nutrition. CMAJ. 1986;134(1):17\u20138.","journal-title":"CMAJ"},{"issue":"4 Pt 1","key":"391_CR11","first-page":"347","volume":"33","author":"JC Lavoie","year":"1993","unstructured":"Lavoie JC, Chessex P. Biologic effects of parenteral bisulfite on human vascular tissue. Pediatr Res. 1993;33(4 Pt 1):347\u201351.","journal-title":"Pediatr Res"},{"issue":"3","key":"391_CR12","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3109\/10408448709071208","volume":"17","author":"AF Gunnison","year":"1987","unstructured":"Gunnison AF, Jacobsen DW. Sulfite hypersensitivity. A critical review. CRC Crit Rev Toxicol. 1987;17(3):185\u2013214.","journal-title":"CRC Crit Rev Toxicol"},{"issue":"2","key":"391_CR13","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jaip.2013.10.002","volume":"2","author":"JP Rajan","year":"2014","unstructured":"Rajan JP, Simon RA, Bosso JV. Prevalence of sensitivity to food and drug additives in patients with chronic idiopathic urticaria. J Allergy Clin Immunol Pract. 2014;2(2):168\u201371.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"7\u20138","key":"391_CR14","doi-asserted-by":"publisher","first-page":"610","DOI":"10.3109\/21678421.2014.959024","volume":"15","author":"K Abe","year":"2014","unstructured":"Abe K, Itoyama Y, Sobue G, Tsuji S, Aoki M, Doyu M, et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(7\u20138):610\u20137.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"suppl 1","key":"391_CR15","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1080\/21678421.2017.1362440","volume":"18","author":"A Kalin","year":"2017","unstructured":"Kalin A, Medina-Paraiso E, Ishizaki K, Kim A, Zhang Y, Saita T, et al. A safety analysis of edaravone (MCI-186) during the first six cycles (24 weeks) of amyotrophic lateral sclerosis (ALS) therapy from the double-blind period in three randomized, placebo-controlled studies. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(suppl 1):71\u20139.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"1","key":"391_CR16","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0091-6749(06)80016-3","volume":"90","author":"B Anibarro","year":"1992","unstructured":"Anibarro B, Caballero T, Garcia-Ara C, Diaz-Pena JM, Ojeda JA. Asthma with sulfite intolerance in children: a blocking study with cyanocobalamin. J Allergy Clin Immunol. 1992;90(1):103\u20139.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"391_CR17","doi-asserted-by":"publisher","first-page":"170 e1\u2013e2","DOI":"10.1016\/j.ajem.2017.10.019","volume":"36","author":"RK Dean","year":"2018","unstructured":"Dean RK, Subedi R, Christiano P, Ghimire A. More than a drink: a rare anaphylactic reaction to sparkling water. Am J Emerg Med. 2018;36(1):170 e1-e2.","journal-title":"Am J Emerg Med"},{"issue":"11","key":"391_CR18","doi-asserted-by":"publisher","first-page":"6207","DOI":"10.1021\/acsomega.0c00425","volume":"5","author":"N Okamoto","year":"2020","unstructured":"Okamoto N, Bito T, Hiura N, Yamamoto A, Iida M, Baba Y, et al. Food additives (hypochlorous acid water, sodium metabisulfite, and sodium sulfite) strongly affect the chemical and biological properties of vitamin B12 in aqueous solution. ACS Omega. 2020;5(11):6207\u201314.","journal-title":"ACS Omega"},{"issue":"14","key":"391_CR19","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1212\/WNL.0b013e3182a6cc13","volume":"81","author":"MR Turner","year":"2013","unstructured":"Turner MR, Goldacre R, Ramagopalan S, Talbot K, Goldacre MJ. Autoimmune disease preceding amyotrophic lateral sclerosis: an epidemiologic study. Neurology. 2013;81(14):1222\u20135.","journal-title":"Neurology"},{"key":"391_CR20","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3389\/fneur.2016.00047","volume":"7","author":"SK Hollinger","year":"2016","unstructured":"Hollinger SK, Okosun IS, Mitchell CS. Antecedent disease and amyotrophic lateral sclerosis: what is protecting whom? Front Neurol. 2016;7:47.","journal-title":"Front Neurol"},{"issue":"9","key":"391_CR21","first-page":"302","volume":"67","author":"EJ Bodar","year":"2009","unstructured":"Bodar EJ, Simon A, de Visser M, van der Meer JW. Complete remission of severe idiopathic cold urticaria on interleukin-1 receptor antagonist (anakinra). Neth J Med. 2009;67(9):302\u20135.","journal-title":"Neth J Med"},{"key":"391_CR22","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/199084a0","volume":"199","author":"D Boehme","year":"1963","unstructured":"Boehme D, Paal G, Kersten W, Kersten H. Skin reaction in children and adults with central nervous system disease after intracutaneous administration of myelin preparations derived from human brain. Nature. 1963;199:84\u20135.","journal-title":"Nature"},{"issue":"1","key":"391_CR23","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1136\/jnnp.54.1.90","volume":"54","author":"PO Behan","year":"1991","unstructured":"Behan PO, Bakheit AM. Association of amyotrophic lateral sclerosis, Hoigne\u2019s syndrome and residence in Guam. J Neurol Neurosurg Psychiatry. 1991;54(1):90\u20131.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"391_CR24","volume":"13","author":"WT Garzon-Siatoya","year":"2021","unstructured":"Garzon-Siatoya WT, Carrillo-Martin I, Rodenas M, Gonzalez-Estrada A. IgE-mediated reaction to levamisole: evaluation of a patient with severe anaphylaxis. Cureus. 2021;13(9): e17815.","journal-title":"Cureus"},{"issue":"11","key":"391_CR25","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S1474-4422(14)70222-4","volume":"13","author":"ME Cudkowicz","year":"2014","unstructured":"Cudkowicz ME, Titus S, Kearney M, Yu H, Sherman A, Schoenfeld D, et al. Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13(11):1083\u201391.","journal-title":"Lancet Neurol"},{"issue":"4","key":"391_CR26","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1017\/ice.2018.8","volume":"39","author":"SS Spires","year":"2018","unstructured":"Spires SS, Rebeiro PF, Miller M, Koss K, Wright PW, Talbot TR. Medically attended catheter complications are common in patients with outpatient central venous catheters. Infect Control Hosp Epidemiol. 2018;39(4):439\u201344.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"1","key":"391_CR27","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1017\/ice.2016.223","volume":"38","author":"SC Keller","year":"2017","unstructured":"Keller SC, Williams D, Gavgani M, Hirsch D, Adamovich J, Hohl D, et al. Environmental exposures and the risk of central venous catheter complications and readmissions in home infusion therapy patients. Infect Control Hosp Epidemiol. 2017;38(1):68\u201375.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"9","key":"391_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162479","volume":"11","author":"P Paras-Bravo","year":"2016","unstructured":"Paras-Bravo P, Paz-Zulueta M, Sarabia-Lavin R, Jose Amo-Setien F, Herrero-Montes M, Olavarria-Beivide E, et al. Complications of peripherally inserted central venous catheters: a retrospective cohort study. PLoS\u00a0One. 2016;11(9): e0162479.","journal-title":"PLoS\u00a0One"},{"issue":"4","key":"391_CR29","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.clnu.2015.06.009","volume":"35","author":"LD Christensen","year":"2016","unstructured":"Christensen LD, Holst M, Bech LF, Drustrup L, Nygaard L, Skallerup A, et al. Comparison of complications associated with peripherally inserted central catheters and Hickman catheters in patients with intestinal failure receiving home parenteral nutrition. Six-year follow up study. Clin Nutr. 2016;35(4):912\u20137.","journal-title":"Clin Nutr"},{"issue":"8","key":"391_CR30","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.12968\/bjon.2020.29.8.S34","volume":"29","author":"O Saqui","year":"2020","unstructured":"Saqui O, Fernandes G, Allard J. Central venous catheter infection in Canadian home parenteral nutrition patients: a 5-year multicenter retrospective study. Br J Nurs. 2020;29(8):S34\u201342.","journal-title":"Br J Nurs"},{"issue":"7\u20138","key":"391_CR31","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1080\/21678421.2018.1517179","volume":"19","author":"J Turnbull","year":"2018","unstructured":"Turnbull J. Is edaravone harmful? (A placebo is not a control). Amyotroph Lateral Scler Frontotemporal Degener. 2018;19(7\u20138):477\u201382.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"3\u20134","key":"391_CR32","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1080\/21678421.2019.1582672","volume":"20","author":"A Genge","year":"2019","unstructured":"Genge A, Brooks B. Edaravone administration in pivotal clinical Study 19. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(3\u20134):298\u20139.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"3\u20134","key":"391_CR33","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1080\/21678421.2019.1582675","volume":"20","author":"J Turnbull","year":"2019","unstructured":"Turnbull J. Author response to a Letter to the Editor entitled: Edaravone administration in pivotal clinical study 19 (Authors: Genge, Angela; Brooks, Benjamin). Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(3\u20134):300\u20132.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"9","key":"391_CR34","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S1474-4422(20)30265-9","volume":"19","author":"J Turnbull","year":"2020","unstructured":"Turnbull J. Reappraisal of an ALS trial: unaccounted procedural risk. Lancet Neurol. 2020;19(9):717\u20138.","journal-title":"Lancet Neurol"},{"issue":"1","key":"391_CR35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1080\/146608202317576507","volume":"3","author":"L Lacomblez","year":"2002","unstructured":"Lacomblez L, Bensimon G, Leigh PN, Debove C, Bejuit R, Truffinet P, et al. Long-term safety of riluzole in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2002;3(1):23\u20139.","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord"},{"issue":"3","key":"391_CR36","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1080\/146608201753275508","volume":"2","author":"C Debove","year":"2001","unstructured":"Debove C, Zeisser P, Salzman PM, Powe LK, Truffinet P. The Rilutek (riluzole) Global Early Access Programme: an open-label safety evaluation in the treatment of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001;2(3):153\u20138.","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord"},{"issue":"1","key":"391_CR37","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/mus.25712","volume":"57","author":"K Nicholson","year":"2018","unstructured":"Nicholson K, Murphy A, McDonnell E, Shapiro J, Simpson E, Glass J, et al. Improving symptom management for people with amyotrophic lateral sclerosis. Muscle Nerve. 2018;57(1):20\u20134.","journal-title":"Muscle Nerve"},{"issue":"5\u20136","key":"391_CR38","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1080\/21678421.2017.1313865","volume":"18","author":"G Santangelo","year":"2017","unstructured":"Santangelo G, Siciliano M, Trojano L, Femiano C, Monsurro MR, Tedeschi G, et al. Apathy in amyotrophic lateral sclerosis: insights from Dimensional Apathy Scale. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(5\u20136):434\u201342.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"1","key":"391_CR39","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s10072-019-04055-3","volume":"41","author":"JM Park","year":"2020","unstructured":"Park JM, Kim SY, Park D, Park JS. Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients. Neurol Sci. 2020;41(1):119\u201323.","journal-title":"Neurol Sci"},{"issue":"11","key":"391_CR40","doi-asserted-by":"publisher","first-page":"3258","DOI":"10.1007\/s00415-020-09993-z","volume":"267","author":"C Lunetta","year":"2020","unstructured":"Lunetta C, Moglia C, Lizio A, Caponnetto C, Dubbioso R, Giannini F, et al. The Italian multicenter experience with edaravone in amyotrophic lateral sclerosis. J Neurol. 2020;267(11):3258\u201367.","journal-title":"J Neurol"},{"issue":"3\u20134","key":"391_CR41","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1080\/21678421.2019.1572191","volume":"20","author":"A Abraham","year":"2019","unstructured":"Abraham A, Nefussy B, Fainmesser Y, Ebrahimi Y, Karni A, Drory VE. Early post-marketing experience with edaravone in an unselected group of patients with ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(3\u20134):260\u20133.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"10","key":"391_CR42","volume":"12","author":"JF Ortiz","year":"2020","unstructured":"Ortiz JF, Khan SA, Salem A, Lin Z, Iqbal Z, Jahan N. Post-marketing experience of edaravone in amyotrophic lateral sclerosis: a clinical perspective and comparison with the clinical trials of the drug. Cureus. 2020;12(10): e10818.","journal-title":"Cureus"},{"key":"391_CR43","unstructured":"Yoshimura K, Ishizaki K, Yoshida K, Matsuda M, Kawaguchi Y, Yuki S, et al. Safety information of patients from ongoing post-marketing surveillance, evaluating the real-world efficacy and safety of edaravone for amyotrophic lateral sclerosis patients in Japan (SUNRISE Japan) (CMS-35). Amyotroph Lateral Scler Frontotemporal Degener. 2020;21(suppl 2)."},{"issue":"suppl 1","key":"391_CR44","first-page":"286","volume":"20","author":"J Berry","year":"2019","unstructured":"Berry J, Brooks B, Genge A, Heiman-Patterson T, Appel S, Benatar M, et al. Protocol and design of the Radicava\u00ae (edaravone) biomarker study for ALS patients in the United States (CLT-40). Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(suppl 1):286\u20137.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"10","key":"391_CR45","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1002\/cpdd.925","volume":"10","author":"H Shimizu","year":"2021","unstructured":"Shimizu H, Nishimura Y, Shiide Y, Matsuda H, Akimoto M, Matsuda M, et al. Evaluation of pharmacokinetics, safety, and drug-drug interactions of an oral suspension of edaravone in healthy adults. Clin Pharmacol Drug Dev. 2021;10(10):1174\u201387.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"10","key":"391_CR46","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1002\/cpdd.952","volume":"10","author":"H Shimizu","year":"2021","unstructured":"Shimizu H, Nishimura Y, Shiide Y, Yoshida K, Hirai M, Matsuda M, et al. Bioequivalence study of oral suspension and intravenous formulation of edaravone in healthy adult subjects. Clin Pharmacol Drug Dev. 2021;10(10):1188\u201397.","journal-title":"Clin Pharmacol Drug Dev"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-022-00391-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-022-00391-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-022-00391-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T14:30:20Z","timestamp":1661956220000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-022-00391-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,20]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["391"],"URL":"https:\/\/doi.org\/10.1007\/s40268-022-00391-6","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,20]]},"assertion":[{"value":"8 May 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Mitsubishi Tanabe Pharma America, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"AG, BRB, and BO are consultants for MTPA. BW, AK, MJ, and LB are employees of Mitsubishi Tanabe Pharma Development America, Inc. SA is an employee of Mitsubishi Tanabe Pharma America, Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors have provided consent for publication of this manuscript.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All data are included in the manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"AG, BRB, and BO contributed to writing, clinical interpretation, and data interpretation. AK and MJ contributed to writing and data analysis and interpretation. SA and LB contributed to writing, clinical interpretation, data analysis, and data interpretation.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}